J Korean Ophthalmol Soc > Volume 60(11); 2019 > Article
Journal of the Korean Ophthalmological Society 2019;60(11):1072-1079.
DOI: https://doi.org/10.3341/jkos.2019.60.11.1072    Published online November 15, 2019.
Comparison of Short-term Effects of Intravitreal Injection of Three Modalities on Central Retinal Vein Occlusion.
Ji Seong Jeong, Dong Woo Lee, Byoung Seon Kim, Woong Sun Yoo, In Young Chung, Jong Moon Park
1Department of Ophthalmology, Gyeongsang National University College of Medicine, Jinju, Korea. parkjm@gnu.ac.kr
2Department of Ophthalmology, Gyeongsang National University Hospital, Jinju, Korea.
3Institute of Health Sciences, Gyeongsang National University, Jinju, Korea.
중심망막정맥폐쇄에 동반된 황반부종에서 유리체내 서로 다른 세 가지 약물의 단기 효과 비교
정지성1,2 · 이동우1,2 · 김병선1,2 · 유웅선1,2,3 · 정인영1,2,3 · 박종문1,2,3
경상대학교 의과대학 안과학교실1, 경상대학교병원 안과2, 경상대학교 건강과학연구원3
Correspondence:  Jong-Moon Park, MD, PhD
Email: parkjm@gnu.ac.kr
Received: 22 May 2019   • Revised: 11 July 2019   • Accepted: 24 October 2019
To report the short-term effects of intravitreal bevacizumab alone, low-dose bevacizumab combined with low-dose triamcinolone injection, and intravitreal dexamethasone implant (Ozurdex®, Allergan, Irvine, CA, USA) injection in patients with macular edema following central retinal vein occlusion (CRVO). METHODS: The medical records of 70 patients (70 eyes) with macular edema secondary to CRVO were reviewed retrospectively. Of these, 25 eyes (IVB group) were injected with intravitreal bevacizumab, 23 eyes (intravitreal low-dose bevacizumab and triamcinolone injection [IVB+IVTA] group) were injected with low-dose bevacizumab (0.625 mg/0.025 mL) combined with low-dose triamcinolone (1 mg/0.025 mL), and 20 eyes (intravitreal dexamethasone implant [IVD] group) were injected with an intravitreal dexamethasone implant. The best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) of treated eyes were measured before injection and at 1 month and 3 months after injection. RESULTS: Groups were similar in age and gender distribution. At 1 month, the CMT of all groups was significantly lower, and the BCVA of all groups had increased significantly in patients with CRVO; there were no significant differences among the three groups (p = 0.246, p = 0.974). At 3 months, the CMT and BCVA had improved significantly only in the IVD and IVB+IVTA groups; the short-term effect was comparable to the IVD group. IOP showed no significant change at 3 months after injection for all groups. CONCLUSIONS: Considering various clinical variables in the treatment of macular edema associated with CRVO, intravitreal injection of bevacizumab, low-dose bevacizumab combined with triamcinolone, and dexamethasone implants may be used selectively.
Key Words: Bevacizumab;Dexamethasone;Intravitreal injections;Retinal vein occlusion;Triamcinolone

Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next